Q-omics provides the consensus-scored SAMD13 profile across patient tissues and cancer cell-line models. SAMD13 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SAMD13 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SAMD13 RNA expression shows 19,256 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where SAMD13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD13 survival associations across molecular data types. SAMD13 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD13 RNA expression–survival associations across cancer types. High SAMD13 expression shows unfavorable associations in LIHC and LUAD, but favorable associations in KIRC, BLCA, GBM and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SAMD13 RNA expression.
This table summarizes SAMD13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SAMD13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD13 shows lower tumor expression in KIRC, KICH, COAD, THCA and HNSC and higher tumor expression in BLCA. The KIRC box plot shows higher SAMD13 RNA expression in normal versus tumor tissue (log2 FC = −0.843, t-test p < 0.001).
This table shows molecular features associated with SAMD13 in patient tissues and cancer cell lines. In patient samples, SAMD13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
